Is Sentinel Lymph Node Biopsy a Viable Alternative to Axillary Lymph Node Dissection in Breast Carcinoma Patients Who Have Received Neo-Adjuvant Chemotherapy?

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2024 Feb 22

PMID 38384601

Authors

Rehena Sulthana

Akshita Singh

Affiliations

Soon will be listed here.

Abstract

Background Sentinel lymph node biopsy (SLNB) is based on the hypothesis that lymph from a primary solid neoplasm drains into one or more sentinel nodes, which are the first nodes at risk for harbouring occult metastatic disease. Sentinel lymph node biopsy has replaced axillary lymph node dissection (ALND) as the standard method for axillary staging in clinically node-negative patients. It avoids the complications associated with ALND and allows assessment of nodal status in patients with clinically node-negative breast cancer. Aims and objectives The aim of this study is to determine the false negative rate and identification rate of SLNB in breast cancer patients who received neoadjuvant chemotherapy (NACT). Materials and methods We conducted a hospital-based prospective study that included 19 patients who presented with early breast cancer and were node-positive. Post NACT, intraoperatively, methylene blue and radiocolloid dye were injected in the subareolar region. During the surgery, the blue and hot nodes identified were dissected, sent for frozen section analysis, and subsequently submitted for histopathological evaluation. This was followed by a standard-level I/II/III axillary clearance with histopathological examination. Results The false-negative rate of SLNB is 25%. Sentinel lymph node biopsy was more accurate with stage II than stage III tumours, and in patients who downstaged from stage II to any stage following NACT, it was more accurate than downstaging from stage III. The average number of sentinel nodes identified was 1.9, with the maximum being seven and the minimum being one. A total of 25 sentinel lymph nodes were identified in 13 patients, with an identification rate of 68.42%. Conclusions The main clinicopathological factors that influence the false negative rate of SLNB after NACT are axillary lymph node status, stage of the tumour at presentation, and tumour downstaging. For patients for whom sentinel nodes cannot be harvested, ALND should be done.

References

Hunt K, Yi M, Mittendorf E, Guerrero C, Babiera G, Bedrosian I . Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg. 2009; 250(4):558-66. DOI: 10.1097/SLA.0b013e3181b8fd5e. View

Dane S, Yildirim S, Koc M, Aktan M, Gundogdu C . Asymmetries in breast cancer lateralization and both axillary lymph node number and metastatic involvement. Lymphology. 2008; 41(2):75-9. View

Gimbergues P, Abrial C, Durando X, Le Bouedec G, Cachin F, Penault-Llorca F . Sentinel lymph node biopsy after neoadjuvant chemotherapy is accurate in breast cancer patients with a clinically negative axillary nodal status at presentation. Ann Surg Oncol. 2008; 15(5):1316-21. DOI: 10.1245/s10434-007-9759-z. View

Gail M, Brinton L, Byar D, Corle D, Green S, Schairer C . Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989; 81(24):1879-86. DOI: 10.1093/jnci/81.24.1879. View

Veronesi U, Paganelli G, Galimberti V, Viale G, Zurrida S, Bedoni M . Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet. 1997; 349(9069):1864-7. DOI: 10.1016/S0140-6736(97)01004-0. View

Munjal K, Ambaye A, Evans M, Mitchell J, Nandedkar S, Cooper K . Immunohistochemical analysis of ER, PR, Her2 and CK5/6 in infiltrative breast carcinomas in Indian patients. Asian Pac J Cancer Prev. 2010; 10(5):773-8. View

Toi M, Ohashi Y, Seow A, Moriya T, Tse G, Sasano H . The Breast Cancer Working Group presentation was divided into three sections: the epidemiology, pathology and treatment of breast cancer. Jpn J Clin Oncol. 2010; 40 Suppl 1:i13-18. DOI: 10.1093/jjco/hyq122. View

Lee S, Kim E, Kang S, Kim S, Kim S, Kang K . Sentinel node identification rate, but not accuracy, is significantly decreased after pre-operative chemotherapy in axillary node-positive breast cancer patients. Breast Cancer Res Treat. 2006; 102(3):283-8. DOI: 10.1007/s10549-006-9330-9. View

Keune J, Jeffe D, Schootman M, Hoffman A, Gillanders W, Aft R . Accuracy of ultrasonography and mammography in predicting pathologic response after neoadjuvant chemotherapy for breast cancer. Am J Surg. 2010; 199(4):477-84. PMC: 3252889. DOI: 10.1016/j.amjsurg.2009.03.012. View

10.

Beck A, Morrow M . Axillary lymph node dissection: Dead or still alive?. Breast. 2023; 69:469-475. PMC: 10300611. DOI: 10.1016/j.breast.2023.01.009. View

11.

Halsted W . I. The Results of Operations for the Cure of Cancer of the Breast Performed at the Johns Hopkins Hospital from June, 1889, to January, 1894. Ann Surg. 1894; 20(5):497-555. PMC: 1493925. DOI: 10.1097/00000658-189407000-00075. View

12.

Gail M, Costantino J, Pee D, Bondy M, Newman L, Selvan M . Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst. 2007; 99(23):1782-92. DOI: 10.1093/jnci/djm223. View

13.

Pamilo M, Soiva M, Lavast E . Real-time ultrasound, axillary mammography, and clinical examination in the detection of axillary lymph node metastases in breast cancer patients. J Ultrasound Med. 1989; 8(3):115-20. DOI: 10.7863/jum.1989.8.3.115. View

14.

Shirzadi A, Mahmoodzadeh H, Qorbani M . Assessment of sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer in two subgroups: Initially node negative and node positive converted to node negative - A systemic review and meta-analysis. J Res Med Sci. 2019; 24:18. PMC: 6421883. DOI: 10.4103/jrms.JRMS_127_18. View

15.

Ban E, Lee J, Koo J, Park S, Kim S, Park B . How many sentinel lymph nodes are enough for accurate axillary staging in t1-2 breast cancer?. J Breast Cancer. 2012; 14(4):296-300. PMC: 3268926. DOI: 10.4048/jbc.2011.14.4.296. View

16.

Spitale A, Mazzola P, Soldini D, Mazzucchelli L, Bordoni A . Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann Oncol. 2008; 20(4):628-35. DOI: 10.1093/annonc/mdn675. View

17.

Chatterjee A, Serniak N, Czerniecki B . Sentinel lymph node biopsy in breast cancer: a work in progress. Cancer J. 2015; 21(1):7-10. PMC: 4304410. DOI: 10.1097/PPO.0000000000000090. View

18.

Kaur N, Sharma P, Garg A, Tandon A . Accuracy of individual descriptors and grading of nodal involvement by axillary ultrasound in patients of breast cancer. Int J Breast Cancer. 2014; 2013:930596. PMC: 3880710. DOI: 10.1155/2013/930596. View

19.

Huo D, Ikpatt F, Khramtsov A, Dangou J, Nanda R, Dignam J . Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol. 2009; 27(27):4515-21. PMC: 2754904. DOI: 10.1200/JCO.2008.19.6873. View

20.

Haque R, Ahmed S, Inzhakova G, Shi J, Avila C, Polikoff J . Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades. Cancer Epidemiol Biomarkers Prev. 2012; 21(10):1848-55. PMC: 3467337. DOI: 10.1158/1055-9965.EPI-12-0474. View